Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Page 1
Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey.
Miyamoto T, Izawa K, Masui S, Yamazaki A, Yamasaki Y, Matsubayashi T, Shiraki M, Ohnishi H, Yasumura J, Kawabe T, Miyamae T, Matsubara T, Arakawa N, Ishige T, Takizawa T, Shimbo A, Shimizu M, Kimura N, Maeda Y, Maruyama Y, Shigemura T, Furuta J, Sato S, Tanaka H, Izumikawa M, Yamamura M, Hasegawa T, Kaneko H, Nakagishi Y, Nakano N, Iida Y, Nakamura T, Wakiguchi H, Hoshina T, Kawai T, Murakami K, Akizuki S, Morinobu A, Ohmura K, Eguchi K, Sonoda M, Ishimura M, Furuno K, Kashiwado M, Mori M, Kawahata K, Hayama K, Shimoyama K, Sasaki N, Ito T, Umebayashi H, Omori T, Nakamichi S, Dohmoto T, Hasegawa Y, Kawashima H, Watanabe S, Taguchi Y, Nakaseko H, Iwata N, Kohno H, Ando T, Ito Y, Kataoka Y, Saeki T, Kaneko U, Murase A, Hattori S, Nozawa T, Nishimura K, Nakano R, Watanabe M, Yashiro M, Nakamura T, Komai T, Kato K, Honda Y, Hiejima E, Yonezawa A, Bessho K, Okada S, Ohara O, Takita J, Yasumi T, Nishikomori R; Japan CAPS Working Group. Miyamoto T, et al. Among authors: shiraki m. Arthritis Rheumatol. 2024 Jan 25. doi: 10.1002/art.42808. Online ahead of print. Arthritis Rheumatol. 2024. PMID: 38268504
Clinical efficacy of assessment of swallowing ability for pneumonia and other assessment tools for occurrence and mortality from pneumonia among older inpatients in a long-term care hospital.
Chojin Y, Okamoto N, Noguchi S, Fube Y, Aritake Y, Shiraki M, Izumitani K, Suzuki M, Omori M, Kato T, Mukae H, Yatera K. Chojin Y, et al. Among authors: shiraki m. Respir Investig. 2023 Sep;61(5):651-659. doi: 10.1016/j.resinv.2023.06.008. Epub 2023 Jul 31. Respir Investig. 2023. PMID: 37531712
CONCLUSION: The ASAP and FIM motor are useful for predicting the occurrence of and mortality from pneumonia in elderly inpatients in long-term care hospitals....
CONCLUSION: The ASAP and FIM motor are useful for predicting the occurrence of and mortality from pneumonia in elderly inpatients in long- …
Prediction of Fracture Risk From Early-Stage Bone Markers in Patients With Osteoporosis Treated With Once-Yearly Administered Zoledronic Acid.
Kasai H, Mori Y, Ose A, Shiraki M, Tanigawara Y. Kasai H, et al. Among authors: shiraki m. J Clin Pharmacol. 2021 May;61(5):606-613. doi: 10.1002/jcph.1774. Epub 2020 Nov 1. J Clin Pharmacol. 2021. PMID: 33135182 Free PMC article. Clinical Trial.
This study aimed to develop a mathematical model quantifying the long-term fracture risk after 2 annual doses of 5 mg of once-yearly administered zoledronic acid or placebo based on the short-term measurement of bone turnover markers or bone mineral density (BMD). . …
This study aimed to develop a mathematical model quantifying the long-term fracture risk after 2 annual doses of 5 mg of once-yearly …
Executive summary of the Japan Osteoporosis Society Guide for the Use of Bone Turnover Markers in the Diagnosis and Treatment of Osteoporosis (2018 Edition).
Nishizawa Y, Miura M, Ichimura S, Inaba M, Imanishi Y, Shiraki M, Takada J, Chaki O, Hagino H, Fukunaga M, Fujiwara S, Miki T, Yoshimura N, Ohta H; from the Japan Osteoporosis Society Bone Turnover Marker Investigation Committee. Nishizawa Y, et al. Among authors: shiraki m. Clin Chim Acta. 2019 Nov;498:101-107. doi: 10.1016/j.cca.2019.08.012. Epub 2019 Aug 16. Clin Chim Acta. 2019. PMID: 31425674 Free article. Review.
However, it is not effective for determining the appropriate treatment options or evaluating short-term treatment efficacy. On the other hand, bone turnover markers (BTMs) have gained attention because they provide information that is valuable for both the selection of tre …
However, it is not effective for determining the appropriate treatment options or evaluating short-term treatment efficacy. On the ot …
A randomized, double-blind, placebo-controlled study of once weekly elcatonin in primary postmenopausal osteoporosis.
Sugimoto T, Shiraki M, Nakano T, Kishimoto H, Ito M, Fukunaga M, Sone T, Hagino H, Miki T, Nishizawa Y, Akachi S, Nakamura T. Sugimoto T, et al. Among authors: shiraki m. Curr Med Res Opin. 2019 Mar;35(3):447-454. doi: 10.1080/03007995.2018.1498780. Epub 2018 Aug 7. Curr Med Res Opin. 2019. PMID: 29986611 Clinical Trial.
OBJECTIVE: Very few reports have described changes in bone mineral density (BMD) with long-term, once weekly administration of elcatonin, and its effects in reducing incident fractures remain unverified. ...
OBJECTIVE: Very few reports have described changes in bone mineral density (BMD) with long-term, once weekly administration of elcato …
Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
Mori Y, Kasai H, Ose A, Serada M, Ishiguro M, Shiraki M, Tanigawara Y. Mori Y, et al. Among authors: shiraki m. Osteoporos Int. 2018 May;29(5):1155-1163. doi: 10.1007/s00198-018-4376-1. Epub 2018 Feb 8. Osteoporos Int. 2018. PMID: 29423715 Free PMC article. Clinical Trial.
Therefore, the aim of this study was to develop a mathematical model predicting long-term BMD after two annual doses of zoledronic acid (ZOL) using the early response of a bone resorption marker in osteoporosis patients. ...
Therefore, the aim of this study was to develop a mathematical model predicting long-term BMD after two annual doses of zoledronic ac …
Bisphosphonates prevent age-related weight loss in Japanese postmenopausal women.
Urano T, Shiraki M, Kuroda T, Tanaka S, Urano F, Uenishi K, Inoue S. Urano T, et al. Among authors: shiraki m. J Bone Miner Metab. 2018 Nov;36(6):734-740. doi: 10.1007/s00774-017-0891-y. Epub 2017 Dec 13. J Bone Miner Metab. 2018. PMID: 29236162

In multiple linear regression analysis, bisphosphonate treatment was a significant independent determinant of percent changes in body weight and BMI (P < 0.01 and P = 0.01, respectively). Long-term use of bisphosphonates prevented reductions in BMI and body weight, usua

…
In multiple linear regression analysis, bisphosphonate treatment was a significant independent determinant of percent changes in body weight …
Treatment responses with once-weekly teriparatide therapy for osteoporosis.
Shiraki M, Ueda S, Sugimoto T, Kuroda T, Nakamura T. Shiraki M, et al. Osteoporos Int. 2016 Oct;27(10):3057-62. doi: 10.1007/s00198-016-3640-5. Epub 2016 May 27. Osteoporos Int. 2016. PMID: 27234671 Free PMC article. Clinical Trial.
CONCLUSIONS: It appears that the LSC could be used as a surrogate efficacy indicator at an earlier stage of treatment, and the absolute criterion of -2.5SD was confirmed as a useful marker of long-term treatment success....
CONCLUSIONS: It appears that the LSC could be used as a surrogate efficacy indicator at an earlier stage of treatment, and the absolute crit …
Preventive effects of raloxifene treatment on agerelated weight loss in postmenopausal women.
Urano T, Shiraki M, Kuroda T, Tanaka S, Uenishi K, Inoue S. Urano T, et al. Among authors: shiraki m. J Bone Miner Metab. 2017 Jan;35(1):108-113. doi: 10.1007/s00774-015-0733-8. Epub 2016 Jan 11. J Bone Miner Metab. 2017. PMID: 26754796 Clinical Trial.
Raloxifene treatment was a significant independent determinant of body weight and BMI. Long-term treatment with raloxifene prevents age-related weight loss....
Raloxifene treatment was a significant independent determinant of body weight and BMI. Long-term treatment with raloxifene prevents a …
Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide.
Takeuchi Y, Kuroda T, Sugimoto T, Shiraki M, Nakamura T. Takeuchi Y, et al. Among authors: shiraki m. Calcif Tissue Int. 2016 Feb;98(2):186-92. doi: 10.1007/s00223-015-0073-7. Epub 2015 Oct 19. Calcif Tissue Int. 2016. PMID: 26478225 Free PMC article. Clinical Trial.
This study suggests that the L-BMD response to once-weekly long-term TPTD treatment is associated with circulating phosphate or with the status of its renal reabsorption. ...
This study suggests that the L-BMD response to once-weekly long-term TPTD treatment is associated with circulating phosphate or with …
34 results